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Risk factors for coronary artery disease, circulating endothe-
lial progenitor cells, and the role of HMG-CoA reductase
inhibitors. Recent studies suggest that postnatal neovascular-
ization relies not exclusively on sprouting of preexisting ves-
sels (“angiogenesis”), but also involves the contribution of
bone marrow–derived circulating endothelial progenitor cells
(EPCs). EPCs can be isolated from peripheral blood or bone
marrow mononuclear cells, CD34+ or CD133+ hematopoietic
progenitors. Infusion of EPCs was shown to promote post-
natal neovascularization of ischemic tissue after myocardial
infarction in animal models and initial clinical trials. Moreover,
circulating endothelial precursor cells can home to denuded ar-
teries after balloon injury and contribute to endothelial regen-
eration, thereby limiting the development of restenosis. Thus,
circulating endothelial cells may exert an important function
as endogenous repair mechanism to maintain the integrity of
the endothelial monolayer and to promote ischemia-induced
neovascularization. However, risk factors for coronary artery
disease, such as diabetes, hypercholesterolemia, and hyperten-
sion are associated with impaired number and function of EPC
in patients with coronary artery disease. Therapeutically, the
reduction of EPC number and the decreased functional activity
in patients with coronary artery disease was counteracted by 3-
hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase
inhibitors (statins), vascular endothelial growth factor (VEGF),
estrogen, or exercise. At the molecular level, these factors are
well established to activate the phosphatidyl-inositol-3-kinase
(PI3K)-Akt-dependent activation of the endothelial nitric ox-
ide synthase (eNOS), suggesting that the PI3K-Akt-eNOS
signaling pathway may be involved in the transduction of
atheroprotective factors. Taken together, the balance of athero-
protective and proatherosclerotic factors may influence EPC
levels and their functional capacity to improve neovasculariza-
tion and endothelial regeneration.
CHARACTERIZATION AND FUNCTION OF
ENDOTHELIAL PROGENITOR CELLS (EPCs)
The growth of blood vessels to provide oxygen supply
for ischemic tissues or tumors in the adult is mediated by
arteriogenesis, angiogenesis or vasculogenesis [1]. Arte-
riogenesis refers to the formation of collateral vessels,
whereas angiogenesis is defined as the growth of new
capillaries by sprouting of preexisting vessels through
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migration and proliferation of mature endothelial cells.
The concept of vasculogenesis was originally described
as de novo blood vessel formation in embryonic devel-
opment. In this context, endothelial precursor cells were
defined as “angioblasts.” Meanwhile, vasculogenesis also
refers to adult blood vessel formation involving the mo-
bilization of bone marrow–derived endothelial progeni-
tor cells, which home to sites of ischemia and contribute
to new blood vessel formation [1]. The finding that vas-
culogenesis contributes to blood vessel formation in the
adult offers novel therapeutic strategies for the use of
circulating EPCs or their precursors for cell therapy of
tissue ischemia [2–5]. Initial studies by Asahara et al
[6] and Shi et al [7] demonstrated that bone marrow–
derived hematopoietic progenitor cells can give rise to
endothelial cells and contribute to endothelial recovery
after balloon injury and new capillary formation after
ischemia. In addition, EPCs can be grown from pe-
ripheral blood mononuclear cells (MNCs) or puri-
fied populations of CD34-positive or CD133-positive
hematopoietic cells [6, 8]. Furthermore, CD14-positive
MNCs have been used as starting population for cul-
tivation of EPCs [9]. EPCs were characterized by the
coexpression of the hematopoietic marker CD34 and en-
dothelial marker proteins such as vascular endothelial
growth factor receptor-2 (VEGFR-2), von Willebrand
factor, VE-cadherin, CD146, and CD31 [4, 6, 10]. More-
over, these cells were defined by their functional capacity
to form endothelial cell colonies and enhanced endothe-
lial nitric oxide synthase (eNOS) expression after shear
stress exposure [7, 11, 12].
The finding that bone marrow–derived cells can home
to sites of ischemia and express endothelial marker pro-
teins has initiated a variety of experimental studies in-
vestigating the function of EPCs in vivo. Infusion of ex
vivo expanded peripheral blood-derived EPCs in nude
mice or rats improved the neovascularization in hind limb
ischemia models [4, 13–15]. Moreover, in animal mod-
els of myocardial infarction, the injection of ex vivo ex-
panded EPCs or stem- and progenitor cells significantly
improved blood flow and reduced left ventricular scar-
ring [14, 16]. Similarly, initial pilot trials indicate that bone
1672
























Fig. 1. Effect of risk factors for coronary artery disease on endothelial progenitor cell (EPC) number and function and potential counteraction.
Abbreviations are: VEGF, vascular endothelial growth factor; EPO, erythropoietin; PPAR-c, peroxisome proliferators-activated receptor-c.
marrow–derived or circulating blood–derived progenitor
cells are useful for therapeutically improving blood sup-
ply of ischemic tissue [5, 17].
The maintenance of the integrity and the functional
activity of the endothelial monolayer are of crucial im-
portance to prevent atherogenesis. Increasing evidence
suggests that risk factors for coronary artery disease en-
hance endothelial cell apoptosis, thereby, disturbing the
endothelial monolayer [18–20]. In the past, the regen-
eration of injured endothelium has been attributed to
the migration and proliferation of mature endothelial
cells. However, recent studies indicate that the injured
endothelial monolayer may also be regenerated by cir-
culating endothelial cells. Indeed, in 1998 Shi et al [7]
have shown that bone marrow–derived cells deriving
from CD34+ hematopoietic stem cells can colonize en-
dothelial flow surfaces of vascular prostheses in a dog
model. In humans, the surface of ventricular assist de-
vices was covered by CD133+/VEGFR2+ hematopoietic
stem cells [21]. EPCs as well as bone marrow–derived
cells home to denuded arteries after balloon injury, ac-
celerate reendothelialization and reduced neointima for-
mation and restenosis (for review see [22]). Interestingly,
a recent study demonstrated that apoptotic bodies from
mature endothelial cells augmented the number and dif-
ferentiation of endothelial progenitor cells postulating
an endogenous mechanism to facilitate the repair of in-
jured endothelium [23]. Whereas the regeneration of the
endothelium by EPC protects atherosclerotic lesion for-
mation, bone marrow–derived stem or progenitor cells
may also contribute to plaque angiogenesis, thereby po-
tentially promoting plaque instability [24]. However, in
a recent study, no influence of bone marrow cell infu-
sion on plaque composition was detected in nonischemic
mice [25]. An increased plaque size was only detected
in the response to ischemia suggesting that ischemia-
induced release of growth factors contribute to this effect
[25].
RISK FACTORS AND EPC
In patients with coronary artery disease the number
of circulating EPCs is significantly reduced [12] (Fig. 1).
Classic risk factors for atherosclerosis such as age or
smoking inversely correlate with the number of circu-
lating CD34/KDR- or CD133/KDR-positive cells [12].
Likewise, the number of ex vivo cultivated peripheral
blood–derived EPCs and the migratory response of this
cultivated EPCs toward VEGF was significantly reduced
in patients with coronary artery disease [12]. Diabetes,
which is a predominant risk factor for coronary artery
disease, impairs CD34+ hematopoietic precursor cells as
well as EPC number and function [26–28]. Thus, two
recent studies have shown that patients with type 1
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[27] or type 2 diabetes [28] revealed lower numbers of
EPCs as assessed by outgrowth assays. Both studies have
shown that the number of EPCs inversely correlated with
haemoglobin A1c (HbA1c) in type 1 and type 2 diabetes
[27, 28]. Moreover, EPCs of type 2 diabetic patients are
impaired in adhesion to the endothelium, proliferation,
and tubulization [28]. Interestingly, the dysfunction of
type 1 diabetic patient-derived EPCs was not reversed by
cultivation in normoglycemic medium. These data sug-
gest that the impairment of EPCs is not reversible by
removal of one harmful factor [27]. The inflammatory
marker protein C-reactive protein (CRP), which is el-
evated in patients with coronary artery disease and di-
abetes, also impaired EPC function and induced EPC
apoptosis in vitro [29].
Interestingly, in healthy subjects classic risk factors for
atherogenesis are also associated with a reduction of
peripheral blood–derived endothelial cells [30]. More-
over, the number of outgrowing endothelial colonies
correlated with the endothelial function as assessed by
measurement of flow-dependent dilation, which is a prog-
nostic parameter for the functional activity of the en-
dothelium in patients with coronary artery disease [30].
First evidence that the reduction of EPCs may have
an impact on neovascularization was provided by a re-
cent study of Lambiase et al [31]. Thereby, an inade-
quate coronary collateral development was associated
with reduced numbers of EPCs and impaired chemo-
tactic and proangiogenic activity suggesting that EPCs
may contribute to functional collateral formation [31].
Taken together, the reduction of EPCs by risk factors
may contribute to a vicious cycle resulting in reduced
endothelial regeneration and function, and impaired
neovascularization.
EFFECT OF 3-HYDROXY-3-METHYLGLUTARYL
COENZYME A (HMG-COA) REDUCTASE
INHIBITORS (STATINS)
A variety of factors, including cytokines [e.g., VEGF,
erythropoietin (EPO), and granulocyte macrophage-
colony-stimulating factor (GM-CSF)], hormones such as
estrogen, and pharmacologic substances like statins and
peroxisome proliferators-activated receptor-c (PPAR-c)
agonists as well as physical training regulate EPC num-
bers [3, 10, 29, 32–35] (Fig. 1). Particularly, HMG-CoA
reductase inhibitors increased the number and the func-
tional activity of EPCs in vitro [10, 36], in mice [10,
36], and in patients with stable coronary artery disease
[37]. Moreover, statin therapy accelerates reendothelial-
ization after balloon injury by improving mobilization
and incorporation of bone marrow–derived EPCs [38,
39]. The lipid-lowering effect of statins may contribute to
the regulation of EPC number and function. However,
at least in mice, the beneficial effects of statins were ob-
served without a change in serum cholesterol levels [40].
Beside lipid lowering statins exert a variety of pleiotropic
effects, including the increase of expression and activity
of eNOS (for review see [41]). These pleiotropic effects
of statins might influence mobilization, proliferation and
apoptosis of EPCs [10, 36, 42]. Particularly, eNOS ap-
pears to contribute to mobilization and functional activ-
ity of EPCs [43]. Thus, the increase in EPC mobilization
and cardiac function by statins was abolished in eNOS-
deficient mice [40]. However, statins additionally affected
the aging of EPC and delayed the onset of senescence at
least in part independently on nitric oxide [42, 44]. The in-
creased expression of the telomere repeat binding factor-
2 induced by statins during ex vivo cultivation of EPCs
may contribute to the delayed senescence and functional
improvement of EPCs [44].
At the molecular level, several studies indicate that the
prosurvival phosphatidyl-inositol-3-kinase (PI3K)/Akt
pathway may play an important role not only in ma-
ture endothelial cells [45] but also in EPCs [10, 42].
Thus, statins, VEGF, EPO, estrogen, and exercise (shear
stress) are well known to augment the PI3K/Akt-pathway
[46–50]. Based on the finding that eNOS is essential
for mobilization of bone marrow–derived stem and pro-
genitor cells [43], one may speculate that these stimuli
may increase progenitor cell mobilization by PI3K/Akt-
dependent activation of the NOS within the bone marrow
stromal cells. Consistent with the requirement of eNOS
for statin-induced mobilization, exercise- and VEGF-
timulated EPC mobilization was also abolished in eNOS-
deficient mice [35, 40, 43].
CONCLUSION
EPCs significantly contribute to adult neovasculariza-
tion after ischemia and to endothelial repair after in-
jury. Risk factors for coronary artery disease impair EPC
number and function. For therapeutic cell therapy the
reduction of EPC number was counteracted by the phar-
macologic intervention with statins, cytokines (VEGF
and EPO), estrogen, and physical activity (exercise). All
these factors activate the PI3K/Akt pathway. Further
downstream the eNOS seems to play an important role
since statin-, exercise-, and VEGF-induced mobilization
of EPCs is blunted in eNOS−/− mice. Understanding the
molecular mechanism will help to modulate EPC number
and function in order to optimize cell therapy for a variety
of vascular diseases, including coronary artery and renal
diseases.
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